Health knowledge made personal
WellPage for Monoclonal Antibody Therapy For Lymphoma
+ Bookmark › Share
Go
Search posts:

Monoclonal Antibody Therapy For Lymphoma - Articles

Initial Lymphoma Treatment Decisions by CancerTeam .. Posted Sun 24 Aug 2008 1:49pm ANNOUNCER: Non-Hodgkin's lymphoma is a cancer of the immune system. ALEXANDRA LEVINE, MD: Lymphoma is a tumor of lymphocytes; that's a type of white blood cell that's normally responsible for your immune system, your defense against germs and other foreign invaders. Normally, the lymphocytes will start dividing if there is something to react aga ... Read on »
Treating Follicular Non-Hodgkin's Lymphoma by CancerTeam .. Posted Sun 24 Aug 2008 1:49pm ALEXANDRA LEVINE, MD: Follicular lymphoma is not unusual at all in the United States. It is a disease that is associated with long survival, even though we cannot traditionally cure it today. MORTON COLEMAN, MD: It tends to be a disease more of the elderly than of the young, but it is possible to see it in patients 30 and 40 years old. ANNO ... Read on »
Deciding Among NHL Treatments by CancerTeam .. Posted Sun 24 Aug 2008 1:49pm JOHN LEONARD, MD: Hello, I'm Dr. John Leonard. I'm the Clinical Director of the Cornell Center for Lymphoma and Myeloma. We're going to talk today about how a patient with indolent or slow-growing non-Hodgkin's lymphoma decides among treatment options when the disease returns or relapses. Joining me today is my Cornell colleague, Dr. Morton Cole ... Read on »
New and Promising NHL Treatments by CancerTeam .. Posted Sun 24 Aug 2008 1:49pm JOHN LEONARD, MD: Hello, I'm Dr. John Leonard. I'm the Clinical Director of the Cornell Center for Lymphoma and Myeloma. We're going to talk today about some of the promising research in the treatments for relapsing indolent or slow-growing non-Hodgkin's lymphoma. Joining me is my Cornell colleague, Dr. Morton Coleman. Dr. Coleman is a Clinical ... Read on »
Campath for T cell lymphomas by Mark Levin Posted Wed 06 Jul 2011 6:10pm Athough alemtuzumab is an anti-B antibody, several phase II studies suggest that it is effective for Tcell lymphoma, particularly, CTCL , and Mycosis Fungoides but also peripheral T-cell lymphoma. NCCN Mycosis Fungoides Guideline refers one to the T0cell guideline and it lists alemtuzumab with a notes that says that "activity has been demons ... Read on »
Personalized Vaccine for Lymphoma Patients Extends Disease-Free Survival by Nearly Two Years by Ed H. Doctor of Pharmacy Posted Mon 06 Dec 2010 6:01pm A personalized vaccine is a powerful therapy to prevent recurrence among certain follicular lymphoma patients, according to the latest results of ongoing research led by the University of Pennsylvania School of Medicine. The new findings show that when these patients – whose tumors are marked by a specific protein that may be present in up to h ... Read on »
Rituxan: Not Just for Cancer? by CancerTeam .. Posted Sun 24 Aug 2008 1:49pm BRETT SCOTT: I'm Brett Scott in Orlando, Florida, site of this year's meeting of the American Society of Hematology. Rituxan is well known to oncologists here as a treatment for non-Hodgkin's lymphoma. But this year several presenters discussed how it's being used to treat blood disorders other than cancer. During the conference I sat down with one ... Read on »
Rituxan for CD20 positive myeloma by Mark Levin Posted Mon 27 Dec 2010 3:15pm Interest in using Rituxan for subsets of myeloma with CD20 positivity, was provoked by a Phase II study of Moreau et al evaluating four weekly infusions of single-agent rituximab (375 mg/m2) therapy in a cohort of patients with CD20+ multiple myeloma (MM) with either stage I, never treated disease, or stage III MM in relapse, or refractory a ... Read on »
Featured Clinical Trial: Targeted Antibody Therapy for Metastatic Adrenocortical Carcinoma by Cancer.gov Posted Mon 01 Nov 2010 9:00pm Targeted Antibody Therapy for Metastatic Adrenocortical Carcinoma Name of the Trial Phase II Randomized Study of Mitotane with Versus without Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12 in Patients with Recurrent, Metastatic, or Primary Unresectable Adrenocortical Carcinoma (UCCRC-16402A) ... Read on »
Targeted Antibody Therapy for Metastatic Adrenocortical Carcinoma by Cancer.gov Posted Tue 02 Nov 2010 12:00am Targeted Antibody Therapy for Metastatic Adrenocortical Carcinoma Name of the Trial Phase II Randomized Study of Mitotane with Versus without Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12 in Patients with Recurrent, Metastatic, or Primary Unresectable Adrenocortical Carcinoma ( ... Read on »